Back to Posts

Back to Posts

June 24, 2022 Agency Alerts

EMA Procedural guidance for variant strain(s) update to vaccines intended for protection against Human coronavirus


8 June 2022
EMA/175959/2021 Rev.2
Human Medicines Division

Regulatory and procedural requirements

Introduction

In order to ensure the continued effectiveness of authorised COVID-19 vaccines, it may be necessary to modify the authorised human coronavirus vaccines composition so as to protect against new or multiple variant strain(s). Such changes, which include the replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences, should be considered as variations to the marketing authorisation in accordance to the Commission Regulation (EC) No 1234/2008 as amended by Commission Delegated Regulation (EU) 2021/756, provided the technological platform of the vaccine remains similar. The same approach should be followed for all human coronaviruses as set out in the Commission Delegated Regulation (EU) 2021/756. This guideline lays down the procedural aspects related to the submission of a variation to change the composition of a marketing authorisation for COVID-19 vaccines in the centralised procedure.

Download Procedural Guidance

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.



ビジネスには複雑な課題があります。ProPharma Groupは優れたソリューションを提供しています。

弊社は製薬企業様、バイオテクノロジー企業様、医療機器メーカー様とともに複雑な課題にチャレンジいたします。弊社の経験豊かな専門スタッフが製品ライフサイクルの全段階で薬事と開発が成功するようにお客様をサポートいたします。詳細はお問い合わせください。

業界で優位性を確保したいとお考えですか? 弊社が最新の競争力を維持するお手伝いをいたします。


すべてのフィールドが必要です。
送信で問題が発生しました。以下にエラーがハイライトされました。